Venatorx Pharmaceuticals to Present Data at IDWeek 2021

Tags:  

MALVERN, Pa.--(BUSINESS WIRE)--Venatorx Pharmaceuticals today announced that the Company, along with its collaborators, will present seven posters and two oral abstracts at IDWeek 2021, which is taking place virtually September 29 – October 3, 2021.

Session A1. Novel Antimicrobial Agents

Session A3. Resistance Mechanisms

Session A4. Treatment of antimicrobial resistant infections

---

---

Session D1. Diagnostics: Bacteriology/mycobacteriology

Session N10. Healthcare-Associated Infections: Gram-Negatives (MDR-GNR)

About Venatorx Pharmaceuticals, Inc.

Founded in 2010, Venatorx Pharmaceuticals is a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with multi-drug-resistant bacterial infections and hard-to-treat viral infections. Venatorx has built a world-class in-house research and development organization that has filed over 120 patents. Venatorx’s two lead antibacterial clinical-stage programs are intravenous (cefepime-taniborbactam) and oral (ceftibuten/VNRX-7145) broad-spectrum beta-lactam / beta-lactamase inhibitor combinations that are in Phase 3 and Phase 1, respectively. In addition, the first Venatorx antiviral compound (VNRX-9945), a Hepatitis B virus inhibitor, is in Phase 1 clinical development. The Company also has discovery-stage programs targeting a novel class of non-beta-lactam antibiotics called Penicillin Binding Protein (PBP) inhibitors that have the potential to circumvent 70+ years of resistance and usher in a new wave of antibacterial therapeutics. For more information about Venatorx, please visit www.venatorx.com.

Contacts

MEDIA CONTACT: Heather Hunter Vice President, Communications hunter(at)venatorx(dot)com 484.329.8327

MEDIA CONTACT: Heather Hunter Vice President, Communications hunter(at)venatorx(dot)com 484.329.8327

---

---